Some outlets are predicting that Eli Lilly's stock will end the year higher, with one specific prediction of reaching $1,200. Another prediction suggests the stock could hit $1,400, citing momentum from tirzepatide. The overall outlook appears to be positive, with some forecasts indicating double-digit upside for the stock.